News

The analysis found that preemptive treatment reduced the incidence rate of grade 2 and greater skin toxicities by over 50% without additional side effects when compared to reactive

The structure of this transaction is expected to be accretive, exclusive of financing costs, in the first full year of operations. Inlog’s management is planning to stay with

Between March and June 2008, 556 patients were screened for the randomized, double-blind, placebo-controlled trial, of which 430 were enrolled. The participants will be observed at 31 clinical

Bucher will handle sales and service in Switzerland of Fluxion’s BioFlux research tools for live cell image analysis in drug discovery. The Fluxion BioFlux 200 system is ideal

Bristol-Myers Squibb initiated a cash tender offer on May 29, 2008, to purchase all outstanding common stock of Kosan for $5.50 per share. The tender offer expired at

In its submission to the Commission’s ongoing pharmaceutical sector inquiry, the European Federation of Pharmaceutical Industries and Associations (EFPIA) has assured the Commission that the perceived decline in

The National Health Service (NHS) has long had a policy that patients who spend their own money for expensive drugs that aren’t reimbursed by the government automatically become

According to projections made by a national commission set up in 1979 to monitor social spending (CCSS), the whole social security system in France is likely to sustain

A report from the Center for Responsive Politics has also revealed that the Pharmaceutical Research and Manufacturers of America (PhRMA) spent $3.61 million on political lobbying during the